The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease.
Journal
Nature reviews. Gastroenterology & hepatology
ISSN: 1759-5053
Titre abrégé: Nat Rev Gastroenterol Hepatol
Pays: England
ID NLM: 101500079
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
07
07
2023
medline:
27
11
2023
pubmed:
16
8
2023
entrez:
15
8
2023
Statut:
ppublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are the leading causes of chronic liver disease worldwide. NAFLD and ALD share pathophysiological, histological and genetic features and both alcohol and metabolic dysfunction coexist as aetiological factors in many patients with hepatic steatosis. A diagnosis of NAFLD requires the exclusion of significant alcohol consumption and other causes of liver disease. However, data suggest that significant alcohol consumption is often under-reported in patients classified as having NAFLD and that alcohol and metabolic factors interact to exacerbate the progression of liver disease. In this Review, we analyse existing data on the interaction between alcohol consumption and metabolic syndrome as well as the overlapping features and differences in the pathogenesis of ALD and NAFLD. We also discuss the clinical implications of the coexistence of alcohol consumption, of any degree, in patients with evidence of metabolic derangement as well as the use of alcohol biomarkers to detect alcohol intake. Finally, we summarize the evolving nomenclature of fatty liver disease and describe a recent proposal to classify patients at the intersection of NAFLD and ALD. We propose that, regardless of the presumed aetiology, patients with fatty liver disease should be evaluated for both metabolic syndrome and alcohol consumption to enable better prognostication and a personalized medicine approach.
Identifiants
pubmed: 37582985
doi: 10.1038/s41575-023-00822-y
pii: 10.1038/s41575-023-00822-y
doi:
Substances chimiques
Ethanol
3K9958V90M
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
764-783Informations de copyright
© 2023. Springer Nature Limited.
Références
Younossi, Z. & Henry, L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology 150, 1778–1785 (2016).
pubmed: 26980624
Griswold, M. G. et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 392, 1015–1035 (2018).
Lindenmeyer, C. C. & McCullough, A. J. The natural history of nonalcoholic fatty liver disease-an evolving view. Clin. Liver Dis. 22, 11–21 (2018).
pubmed: 29128051
pmcid: 6130315
Loomba, R. et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment. Pharmacol. Ther. 51, 1149–1159 (2020).
pubmed: 32372515
Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559–1569 (2021).
pubmed: 34670043
pmcid: 8881985
Parker, R. The natural history of alcohol-related liver disease. Curr. Opin. Gastroenterol. 36, 164–168 (2020).
pubmed: 32073504
Younossi, Z. M. et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin. Gastroenterol. Hepatol. 19, 580–589.e5 (2021).
pubmed: 32531342
Burra, P., Becchetti, C. & Germani, G. NAFLD and liver transplantation: disease burden, current management and future challenges. JHEP Rep. 2, 100192 (2020).
pubmed: 33163950
pmcid: 7607500
Rinella, M. E. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77, 1797–1835 (2023).
pubmed: 36727674
Mitra, S., De, A. & Chowdhury, A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl. Gastroenterol. Hepatol. 5, 16 (2020).
pubmed: 32258520
pmcid: 7063528
Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335–1347 (2023).
pubmed: 36626630
Henry, L., Paik, J. & Younossi, Z. M. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment. Pharmacol. Ther. 56, 942–956 (2022).
pubmed: 35880713
Le, M. H. et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 20, 2809–2817 (2021).
pubmed: 34890795
World Health Organization. Global Status Report on Alcohol and Health 2018 (World Health Organization, 2019).
Arab, J. P. et al. NAFLD: challenges and opportunities to address the public health problem in Latin America. Ann. Hepatol. 24, 100359 (2021).
pubmed: 34004366
Ayares, G. et al. Public health measures and prevention of alcohol-associated liver disease. J. Clin. Exp. Hepatol. 12, 1480–1491 (2022).
pubmed: 36340308
pmcid: 9630023
Julien, J., Ayer, T., Bethea, E. D., Tapper, E. B. & Chhatwal, J. Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study. Lancet Public Health 5, e316–e323 (2020).
pubmed: 32504584
Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A. J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123–133 (2018).
pubmed: 28802062
Huang, D. Q., El-Serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, 223–238 (2021).
pubmed: 33349658
Huang, D. Q., Mathurin, P., Cortez-Pinto, H. & Loomba, R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat. Rev. Gastroenterol. Hepatol. 20, 37–49 (2023).
pubmed: 36258033
Huang, D. Q. et al. Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 21, 1169–1177 (2022).
pubmed: 35940513
Díaz, L. A. et al. Impact of public health policies on alcohol-associated liver disease in Latin America: an ecological multi-national study. Hepatology 74, 2478–2490 (2021).
pubmed: 34134172
Lazarus, J. V. et al. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? J. Hepatol. 76, 771–780 (2021).
pubmed: 34895743
Díaz, L. A. et al. The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. Lancet Gastroenterol. Hepatol. 7, 552–559 (2022).
pubmed: 35430032
Idalsoaga, F., Kulkarni, A. V., Mousa, O. Y., Arrese, M. & Arab, J. P. Non-alcoholic fatty liver disease and alcohol-related liver disease: two intertwined entities. Front. Med. 7, 448 (2020).
Lu, F.-B. et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev. Gastroenterol. Hepatol. 12, 491–502 (2018).
pubmed: 29609501
Arrese, M., Barrera, F., Triantafilo, N. & Arab, J. P. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Rev. Gastroenterol. Hepatol. 13, 849–866 (2019).
pubmed: 31353974
Åberg, F., Byrne, C. D., Pirola, C. J., Männistö, V. & Sookoian, S. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease. J. Hepatol. 78, 191–206 (2022).
pubmed: 36063967
Younossi, Z. M. et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin. Gastroenterol. Hepatol. 17, 1625–1633.e1 (2019).
pubmed: 30476585
Inan-Eroglu, E. et al. Joint associations of adiposity and alcohol consumption with liver disease-related morbidity and mortality risk: findings from the UK Biobank. Eur. J. Clin. Nutr. 76, 74–83 (2022).
pubmed: 34059777
Staufer, K. et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J. Hepatol. 77, 918–930 (2022).
pubmed: 35605744
Ajmera, V. H., Terrault, N. A. & Harrison, S. A. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology 65, 2090–2099 (2017).
pubmed: 28100008
Magherman, L. et al. Meta-analysis: the impact of light-to-moderate alcohol consumption on progressive non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 57, 820–836 (2023).
pubmed: 36708129
NIAAA. Drinking Levels Defined. NIH https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking (2023).
Arab, J. P. et al. Alcohol-related liver disease: clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). Ann. Hepatol. 18, 518–535 (2019).
pubmed: 31053546
Osna, N. A., Donohue, T. M. Jr & Kharbanda, K. K. Alcoholic liver disease: pathogenesis and current management. Alcohol. Res. 38, 147–161 (2017).
pubmed: 28988570
pmcid: 5513682
Bajaj, J. S. & Nagy, L. E. Natural history of alcohol-associated liver disease: understanding the changing landscape of pathophysiology and patient care. Gastroenterology 163, 840–851 (2022).
pubmed: 35598629
O’Shea, R. S., Dasarathy, S. & McCullough, A. J.; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 51, 307–328 (2010).
pubmed: 20034030
Shah, N. D. et al. Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin. Gastroenterol. Hepatol. 17, 2320–2329.e12 (2019).
pubmed: 30708110
pmcid: 6682466
Bataller, R., Arab, J. P. & Shah, V. H. Alcohol-associated hepatitis. N. Engl. J. Med. 387, 2436–2448 (2022).
pubmed: 36577100
Di Castelnuovo, A. et al. Alcohol intake and total mortality in 142 960 individuals from the MORGAM project: a population-based study. Addiction 117, 312–325 (2022).
pubmed: 34105209
Rumgay, H. et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. Lancet Oncol. 22, 1071–1080 (2021).
pubmed: 34270924
pmcid: 8324483
Bagnardi, V. et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br. J. Cancer 112, 580–593 (2015).
pubmed: 25422909
Roerecke, M. et al. Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis. Am. J. Gastroenterol. 114, 1574–1586 (2019).
pubmed: 31464740
pmcid: 6776700
Rehm, J. et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 29, 437–445 (2010).
pubmed: 20636661
Hagström, H., Thiele, M., Roelstraete, B., Söderling, J. & Ludvigsson, J. F. Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients. Gut 70, 170–179 (2021).
pubmed: 32220902
Wood, A. M. et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 391, 1513–1523 (2018).
pubmed: 29676281
pmcid: 5899998
Bryazka, D. et al. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet 400, 185–235 (2022).
European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J. Hepatol. 57, 399–420 (2012).
Hagström, H., Hemmingsson, T., Discacciati, A. & Andreasson, A. Alcohol consumption in late adolescence is associated with an increased risk of severe liver disease later in life. J. Hepatol. 68, 505–510 (2018).
pubmed: 29395457
Tapper, E. B. & Parikh, N. D. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ 362, k2817 (2018).
pubmed: 30021785
pmcid: 6050518
Rehm, J. & Monteiro, M. Alcohol consumption and burden of disease in the Americas: implications for alcohol policy. Rev. Panam. Salud Publica 18, 241–248 (2005).
pubmed: 16354420
Singal, A. K. et al. Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. Aliment. Pharmacol. Ther. 54, 451–461 (2021).
pubmed: 34247424
Julien, J. et al. Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: a modeling study. Hepatology 75, 1480–1490 (2022).
pubmed: 34878683
Neufeld, M. et al. Impact of introducing a minimum alcohol tax share in retail prices on alcohol-attributable mortality in the WHO European region: a modelling study. Lancet Reg. Health Eur. 15, 100325 (2022).
pubmed: 35558995
pmcid: 9088199
Anouti, A. & Mellinger, J. L. The changing epidemiology of alcohol-associated liver disease: gender, race, and risk factors. Semin. Liver Dis. 43, 50–59 (2023).
pubmed: 36529138
Naveau, S. et al. Excess weight risk factor for alcoholic liver disease. Hepatology 25, 108–111 (1997).
pubmed: 8985274
Raynard, B. et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35, 635–638 (2002).
pubmed: 11870378
Hart, C. L., Morrison, D. S., Batty, G. D., Mitchell, R. J. & Davey Smith, G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 340, c1240 (2010).
pubmed: 20223873
pmcid: 2837144
Innes, H. et al. Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity. Hepatology 75, 369–378 (2022).
pubmed: 34453350
Allen, A. M. et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology 67, 1726–1736 (2018).
pubmed: 28941364
Whitfield, J. B. et al. Obesity, diabetes, coffee, tea, and cannabis use alter risk for alcohol-related cirrhosis in 2 large cohorts of high-risk drinkers. Am. J. Gastroenterol. 116, 106–115 (2021).
pubmed: 32868629
Mallet, V. et al. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. J. Hepatol. 76, 265–274 (2022).
pubmed: 34606913
Delacôte, C. et al. A model to identify heavy drinkers at high risk for liver disease progression. Clin. Gastroenterol. Hepatol. 18, 2315–2323.e6 (2020).
pubmed: 31931181
Ganne-Carrié, N. et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J. Hepatol. 69, 1274–1283 (2018).
pubmed: 30092234
Ascha, M. S. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51, 1972–1978 (2010).
pubmed: 20209604
Loomba, R. et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am. J. Epidemiol. 177, 333–342 (2013).
pubmed: 23355498
pmcid: 3626057
Dunn, W. et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J. Hepatol. 57, 384–391 (2012).
pubmed: 22521357
pmcid: 3399018
Sookoian, S., Castaño, G. O. & Pirola, C. J. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut 63, 530–532 (2014).
pubmed: 24026352
Åberg, F. et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology 71, 835–848 (2020).
pubmed: 31323122
Hoek, A. G., van Oort, S., Mukamal, K. J. & Beulens, J. W. J. Alcohol consumption and cardiovascular disease risk: placing new data in context. Curr. Atheroscler. Rep. 24, 51–59 (2022).
pubmed: 35129737
pmcid: 8924109
Trépo, E. & Valenti, L. Update on NAFLD genetics: from new variants to the clinic. J. Hepatol. 72, 1196–1209 (2020).
pubmed: 32145256
Jarvis, H. et al. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open. 12, e049767 (2022).
pubmed: 34983755
pmcid: 8728442
Hajifathalian, K., Torabi Sagvand, B. & McCullough, A. J. Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study. Hepatology 70, 511–521 (2019).
pubmed: 30125379
Chang, Y. et al. Low levels of alcohol consumption, obesity, and development of fatty liver with and without evidence of advanced fibrosis. Hepatology 71, 861–873 (2020).
pubmed: 31325180
Blomdahl, J., Nasr, P., Ekstedt, M. & Kechagias, S. Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD. Hepatol. Commun. 7, e0003 (2023).
pubmed: 36633482
pmcid: 9833449
Schuster, S., Cabrera, D., Arrese, M. & Feldstein, A. E. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15, 349–364 (2018).
pubmed: 29740166
Gao, B., Ahmad, M. F., Nagy, L. E. & Tsukamoto, H. Inflammatory pathways in alcoholic steatohepatitis. J. Hepatol. 70, 249–259 (2019).
pubmed: 30658726
pmcid: 6361545
Greuter, T., Malhi, H., Gores, G. J. & Shah, V. H. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight 2, e95354 (2017).
pubmed: 28878132
pmcid: 5621906
Bedossa, P. Pathology of non-alcoholic fatty liver disease. Liver Int. 37, 85–89 (2017).
pubmed: 28052629
Mashek, D. G., Khan, S. A., Sathyanarayan, A., Ploeger, J. M. & Franklin, M. P. Hepatic lipid droplet biology: getting to the root of fatty liver. Hepatology 62, 964–967 (2015).
pubmed: 25854913
Gluchowski, N. L., Becuwe, M., Walther, T. C. & Farese, R. V. Jr. Lipid droplets and liver disease: from basic biology to clinical implications. Nat. Rev. Gastroenterol. Hepatol. 14, 343–355 (2017).
pubmed: 28428634
pmcid: 6319657
Arab, J. P., Arrese, M. & Trauner, M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu. Rev. Pathol. 13, 321–350 (2018).
pubmed: 29414249
Lee, E., Korf, H. & Vidal-Puig, A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J. Hepatol. 78, 1048–1062 (2023).
pubmed: 36740049
Dearlove, D. J. & Hodson, L. Intrahepatic triglyceride content: influence of metabolic and genetics drivers. Curr. Opin. Clin. Nutr. Metab. Care 25, 241–247 (2022).
pubmed: 35762159
Ipsen, D. H., Lykkesfeldt, J. & Tveden-Nyborg, P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell. Mol. Life Sci. 75, 3313–3327 (2018).
pubmed: 29936596
pmcid: 6105174
Lambert, J. E., Ramos-Roman, M. A., Browning, J. D. & Parks, E. J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146, 726–735 (2014).
pubmed: 24316260
Jeon, S. & Carr, R. Alcohol effects on hepatic lipid metabolism. J. Lipid Res. 61, 470–479 (2020).
pubmed: 32029510
pmcid: 7112138
Mathur, M. et al. Adipose lipolysis is important for ethanol to induce fatty liver in the National Institute on Alcohol Abuse and Alcoholism murine model of chronic and binge ethanol feeding. Hepatology 77, 1688–1701 (2022).
Ferdouse, A. & Clugston, R. D. Pathogenesis of alcohol-associated fatty liver: lessons from transgenic mice. Front. Physiol. 13, 940974 (2022).
pubmed: 35864895
pmcid: 9294393
Clugston, R. D. et al. CD36-deficient mice are resistant to alcohol- and high-carbohydrate-induced hepatic steatosis. J. Lipid Res. 55, 239–246 (2014).
pubmed: 24280415
pmcid: 3886662
Barbier-Torres, L. et al. Depletion of mitochondrial methionine adenosyltransferase α1 triggers mitochondrial dysfunction in alcohol-associated liver disease. Nat. Commun. 13, 557 (2022).
pubmed: 35091576
pmcid: 8799735
Fromenty, B. & Roden, M. Mitochondrial alterations in fatty liver diseases. J. Hepatol. 78, 415–429 (2022).
pubmed: 36209983
Williams, B. et al. A novel role for ceramide synthase 6 in mouse and human alcoholic steatosis. FASEB J. 32, 130–142 (2018).
pubmed: 28864659
Hajduch, E., Lachkar, F., Ferré, P. & Foufelle, F. Roles of ceramides in non-alcoholic fatty liver disease. J. Clin. Med. Res. 10, 792 (2021).
Singal, A. K., Shah, V. H. & Malhi, H. Emerging targets for therapy in ALD: lessons from NASH. Hepatology https://doi.org/10.1097/HEP.0000000000000381 (2023).
doi: 10.1097/HEP.0000000000000381
pubmed: 37401857
Gautheron, J., Gores, G. J. & Rodrigues, C. M. P. Lytic cell death in metabolic liver disease. J. Hepatol. 73, 394–408 (2020).
pubmed: 32298766
pmcid: 7371520
Ibrahim, S. H., Hirsova, P. & Gores, G. J. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut 67, 963–972 (2018).
pubmed: 29367207
Musso, G., Cassader, M., Paschetta, E. & Gambino, R. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology 155, 282–302.e8 (2018).
pubmed: 29906416
Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H. & Moshage, H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol. Int. 15, 21–35 (2021).
pubmed: 33548031
Arrese, M., Cabrera, D., Kalergis, A. M. & Feldstein, A. E. Innate immunity and inflammation in NAFLD/NASH. Dig. Dis. Sci. 61, 1294–1303 (2016).
pubmed: 26841783
pmcid: 4948286
Peiseler, M. et al. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J. Hepatol. 77, 1136–1160 (2022).
pubmed: 35750137
Hirsova, P. & Gores, G. J. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol. Gastroenterol. Hepatol. 1, 17–27 (2015).
pubmed: 25729762
Feldstein, A. E. & Gores, G. J. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front. Biosci. 10, 3093–3099 (2005).
pubmed: 15970563
Idrissova, L. et al. TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess. J. Hepatol. 62, 1156–1163 (2015).
pubmed: 25445398
Hatting, M. et al. Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents. Hepatology 57, 2189–2201 (2013).
pubmed: 23339067
Eguchi, A., De Mollerat Du Jeu, X., Johnson, C. D., Nektaria, A. & Feldstein, A. E. Liver bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis. J. Hepatol. 64, 699–707 (2016).
pubmed: 26555271
Wiering, L. & Tacke, F. Treating inflammation to combat non-alcoholic fatty liver disease. J. Endocrinol. 256, e220194 (2022).
pubmed: 36259984
Vitale, I. et al. Apoptotic cell death in disease-current understanding of the NCCD 2023. Cell Death Differ. 30, 1097–1154 (2023).
pubmed: 37100955
pmcid: 10130819
Shojaie, L., Iorga, A. & Dara, L. Cell death in liver diseases: a review. Int. J. Mol. Sci. 21, 9682 (2020).
pubmed: 33353156
pmcid: 7766597
Schwabe, R. F. & Luedde, T. Apoptosis and necroptosis in the liver: a matter of life and death. Nat. Rev. Gastroenterol. Hepatol. 15, 738–752 (2018).
pubmed: 30250076
pmcid: 6490680
Miyata, T. & Nagy, L. E. Programmed cell death in alcohol-associated liver disease. Clin. Mol. Hepatol. 26, 618–625 (2020).
pubmed: 32951412
pmcid: 7641549
Wu, X. et al. Recent advances in understanding of pathogenesis of alcohol-associated liver disease. Annu. Rev. Pathol. 18, 411–438 (2023).
pubmed: 36270295
Wu, Y. et al. Molecular mechanisms of autophagy and implications in liver diseases. Liver Res. 7, 56–70 (2023).
Chao, X. et al. Impaired TFEB-mediated lysosome biogenesis and autophagy promote chronic ethanol-induced liver injury and steatosis in mice. Gastroenterology 155, 865–879.e12 (2018).
pubmed: 29782848
Las, G., Serada, S. B., Wikstrom, J. D., Twig, G. & Shirihai, O. S. Fatty acids suppress autophagic turnover in β-cells. J. Biol. Chem. 286, 42534–42544 (2011).
pubmed: 21859708
pmcid: 3234912
Sutti, S. & Albano, E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 17, 81–92 (2020).
pubmed: 31605031
Shaker, M. E. The contribution of sterile inflammation to the fatty liver disease and the potential therapies. Biomed. Pharmacother. 148, 112789 (2022).
pubmed: 35272137
Thibaut, R. et al. Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. FEBS J. 289, 3024–3057 (2022).
pubmed: 33860630
Wen, Y., Lambrecht, J., Ju, C. & Tacke, F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell. Mol. Immunol. 18, 45–56 (2021).
pubmed: 33041338
Liu, K., Wang, F.-S. & Xu, R. Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell. Mol. Immunol. 18, 38–44 (2021).
pubmed: 33159158
Talukdar, S. et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat. Med. 18, 1407–1412 (2012).
pubmed: 22863787
pmcid: 3491143
Hilscher, M. B. et al. Mechanical stretch increases expression of CXCL1 in liver sinusoidal endothelial cells to recruit neutrophils, generate sinusoidal microthombi, and promote portal hypertension. Gastroenterology 157, 193–209.e9 (2019).
pubmed: 30872106
Hwang, S., Yun, H., Moon, S., Cho, Y. E. & Gao, B. Role of neutrophils in the pathogenesis of nonalcoholic steatohepatitis. Front. Endocrinol. 12, 751802 (2021).
Deczkowska, A. et al. XCR1
pubmed: 34017133
Dudek, M. et al. Auto-aggressive CXCR6
pubmed: 33762736
Li, S. et al. Recent insights into the role of immune cells in alcoholic liver disease. Front. Immunol. 10, 1328 (2019).
pubmed: 31244862
pmcid: 6581703
Marrero, I. et al. Differential activation of unconventional T cells, including iNKT cells, in alcohol-related liver disease. Alcohol. Clin. Exp. Res. 44, 1061–1074 (2020).
pubmed: 32154597
pmcid: 7211132
Wang, H., Mehal, W., Nagy, L. E. & Rotman, Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell. Mol. Immunol. 18, 73–91 (2021).
pubmed: 33268887
Bala, S., Marcos, M., Gattu, A., Catalano, D. & Szabo, G. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS ONE 9, e96864 (2014).
pubmed: 24828436
pmcid: 4020790
Liu, M. et al. Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. Nat. Commun. 12, 4560 (2021).
pubmed: 34315876
pmcid: 8316465
Szabo, G. & Iracheta-Vellve, A. Inflammasome activation in the liver: focus on alcoholic and non-alcoholic steatohepatitis. Clin. Res. Hepatol. Gastroenterol. 39, S18–S23 (2015).
pubmed: 26216030
Knorr, J., Wree, A., Tacke, F. & Feldstein, A. E. The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis. Semin. Liver Dis. 40, 298–306 (2020).
pubmed: 32526788
Ganz, M. & Szabo, G. Immune and inflammatory pathways in NASH. Hepatol. Int. 7, 771–781 (2013).
pubmed: 24587847
Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397–411 (2017).
pubmed: 28487545
Schwabe, R. F., Tabas, I. & Pajvani, U. B. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology 158, 1913–1928 (2020).
pubmed: 32044315
Hernández, A. et al. Extracellular vesicles in NAFLD/ALD: from pathobiology to therapy. Cells 9, 817 (2020).
pubmed: 32231001
pmcid: 7226735
Eguchi, A., Iwasa, M. & Nakagawa, H. Extracellular vesicles in fatty liver disease and steatohepatitis: role as biomarkers and therapeutic targets. Liver Int. 43, 292–298 (2023).
pubmed: 36462157
Wu, D., Zhu, H. & Wang, H. Extracellular vesicles in non-alcoholic fatty liver disease and alcoholic liver disease. Front. Physiol. 12, 707429 (2021).
pubmed: 34335310
pmcid: 8316622
Miyaaki, H. et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int. 34, e302–e307 (2014).
pubmed: 24313922
Szabo, G. & Bala, S. MicroRNAs in liver disease. Nat. Rev. Gastroenterol. Hepatol. 10, 542–552 (2013).
pubmed: 23689081
pmcid: 4091636
Betrapally, N. S., Gillevet, P. M. & Bajaj, J. S. Changes in the intestinal microbiome and alcoholic and nonalcoholic liver diseases: causes or effects? Gastroenterology 150, 1745–1755.e3 (2016).
pubmed: 26948887
Sharpton, S. R., Ajmera, V. & Loomba, R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin. Gastroenterol. Hepatol. 17, 296–306 (2019).
pubmed: 30196156
Leung, H. et al. Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci. Transl. Med. 14, eabk0855 (2022).
pubmed: 35675435
pmcid: 9746350
Jennison, E. & Byrne, C. D. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin. Mol. Hepatol. 27, 22–43 (2021).
pubmed: 33291863
Liu, Y. et al. Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting. Cell Metab. 34, 719–730.e4 (2022).
pubmed: 35354069
pmcid: 9097589
Oh, T. G. et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab. 32, 901 (2020).
pubmed: 33147487
pmcid: 7891106
Fairfield, B. & Schnabl, B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep. 3, 100220 (2021).
pubmed: 33598648
Jew, M. H. & Hsu, C. L. Alcohol, the gut microbiome, and liver disease. J. Gastroenterol. Hepatol. https://doi.org/10.1111/jgh.16199 (2023).
doi: 10.1111/jgh.16199
pubmed: 37096652
Leclercq, S. et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc. Natl Acad. Sci. USA 111, E4485–E4493 (2014).
pubmed: 25288760
pmcid: 4210345
Mutlu, E. A. et al. Colonic microbiome is altered in alcoholism. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G966–G978 (2012).
pubmed: 22241860
pmcid: 3362077
Maccioni, L. et al. Duodenal CD8
pubmed: 35919965
pmcid: 9398988
Zhu, L. et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57, 601–609 (2013).
pubmed: 23055155
Meijnikman, A. S. et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat. Med. 28, 2100–2106 (2022).
pubmed: 36216942
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F. & Staels, B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89, 147–191 (2009).
pubmed: 19126757
Henry, Z., Meadows, V. & Guo, G. L. FXR and NASH: an avenue for tissue-specific regulation. Hepatol. Commun. 7, e0127 (2023).
pubmed: 37058105
pmcid: 10109454
Jahn, D., Rau, M., Hermanns, H. M. & Geier, A. Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. Cytokine Growth Factor Rev. 26, 625–635 (2015).
pubmed: 26250749
Ferrebee, C. B. & Dawson, P. A. Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids. Acta Pharm. Sin. B 5, 129–134 (2015).
pubmed: 26579438
pmcid: 4629214
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M. & Trauner, M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 65, 350–362 (2017).
pubmed: 27358174
Way, G. W., Jackson, K. G., Muscu, S. R. & Zhou, H. Key signaling in alcohol-associated liver disease: the role of bile acids. Cells 11, 1374 (2022).
pubmed: 35456053
pmcid: 9031669
Yang, X., Gonzalez, F. J., Huang, M. & Bi, H. Nuclear receptors and non-alcoholic fatty liver disease: an update. Liver Res. 4, 88–93 (2020).
Francque, S. et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat. Rev. Gastroenterol. Hepatol. 18, 24–39 (2021).
pubmed: 33093663
Berthier, A., Johanns, M., Zummo, F. P., Lefebvre, P. & Staels, B. PPARs in liver physiology. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166097 (2021).
pubmed: 33524529
Fischer, M., You, M., Matsumoto, M. & Crabb, D. W. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J. Biol. Chem. 278, 27997–28004 (2003).
pubmed: 12791698
Yu, S., Rao, S. & Reddy, J. K. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr. Mol. Med. 3, 561–572 (2003).
pubmed: 14527087
Ajmera, V. & Loomba, R. Advances in the genetics of nonalcoholic fatty liver disease. Curr. Opin. Gastroenterol. 39, 150–155 (2023).
pubmed: 37144531
Kim, H.-S. et al. Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality. JAMA Netw. Open. 5, e2234221 (2022).
pubmed: 36190732
pmcid: 9530967
Pennisi, G., Celsa, C., Giammanco, A., Spatola, F. & Petta, S. The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: screening issue and future perspectives. Int. J. Mol. Sci. 20, 5613 (2019).
pubmed: 31717576
pmcid: 6887792
Gellert-Kristensen, H. et al. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology 72, 845–856 (2020).
pubmed: 32190914
Amangurbanova, M., Huang, D. Q. & Loomba, R. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. Aliment. Pharmacol. Ther. 57, 37–51 (2023).
pubmed: 36349732
Chen, H. et al. Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population. Liver Int. 40, 2194–2202 (2020).
pubmed: 33151633
pmcid: 7496237
Stickel, F. et al. Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers. Hepatology 72, 88–102 (2020).
pubmed: 31630428
Pirola, C. J. & Sookoian, S. Epigenetics factors in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 16, 521–536 (2022).
pubmed: 32476509
Rodríguez-Sanabria, J. S., Escutia-Gutiérrez, R., Rosas-Campos, R., Armendáriz-Borunda, J. S. & Sandoval-Rodríguez, A. An update in epigenetics in metabolic-associated fatty liver disease. Front. Med. 8, 770504 (2021).
Hardy, T. & Mann, D. A. Epigenetics in liver disease: from biology to therapeutics. Gut 65, 1895–1905 (2016).
pubmed: 27624887
Habash, N. W., Sehrawat, T. S., Shah, V. H. & Cao, S. Epigenetics of alcohol-related liver diseases. JHEP Rep. 4, 100466 (2022).
pubmed: 35462859
pmcid: 9018389
Arrese, M. et al. Insights into nonalcoholic fatty-liver disease heterogeneity. Semin. Liver Dis. 41, 421–434 (2021).
pubmed: 34233370
pmcid: 8492194
Ma, J. et al. Distinct histopathological phenotypes of severe alcoholic hepatitis suggest different mechanisms driving liver injury and failure. J. Clin. Invest. 132, e157780 (2022).
pubmed: 35838051
pmcid: 9282929
Pirola, C. J. & Sookoian, S. Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making. Expert Rev. Gastroenterol. Hepatol. 17, 317–324 (2023).
pubmed: 36912694
Xu, J. et al. Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J. Hepatol. 55, 673–682 (2011).
pubmed: 21256905
pmcid: 3094601
Benedé-Ubieto, R. et al. An experimental DUAL model of advanced liver damage. Hepatol. Commun. 5, 1051–1068 (2021).
pubmed: 34141989
pmcid: 8183170
Gäbele, E. et al. A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis. Alcohol. Clin. Exp. Res. 35, 1361–1367 (2011).
pubmed: 21463337
Hwang, S., Ren, T. & Gao, B. Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: a model of high-fat diet and binge ethanol intake. Clin. Mol. Hepatol. 26, 586–594 (2020).
pubmed: 32937687
pmcid: 7641546
Israelsen, M. et al. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication. JHEP Rep. 3, 100325 (2021).
pubmed: 34401690
pmcid: 8350545
Liebe, R. et al. Diagnosis and management of secondary causes of steatohepatitis. J. Hepatol. 74, 1455–1471 (2021).
pubmed: 33577920
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of alcohol-related liver disease. J. Hepatol. 69, 154–181 (2018).
Dunn, W. et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 131, 1057–1063 (2006).
pubmed: 17030176
Hahn, J. A. et al. Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: an individual patient data meta-analysis. Alcohol. Clin. Exp. Res. 45, 1166–1187 (2021).
pubmed: 33837975
pmcid: 8254773
Cabezas, J., Lucey, M. R. & Bataller, R. Biomarkers for monitoring alcohol use. Clin. Liver Dis. 8, 59–63 (2016).
Fakhari, S. & Waszkiewicz, N. Old and new biomarkers of alcohol abuse: narrative review. J. Clin. Med. 12, 2124 (2023).
pubmed: 36983134
pmcid: 10054673
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).
Arab, J. P. et al. Latin American Association for the Study of the Liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Ann. Hepatol. 19, 674–690 (2020).
pubmed: 33031970
Bianco, C., Casirati, E., Malvestiti, F. & Valenti, L. Genetic predisposition similarities between NASH and ASH: identification of new therapeutic targets. JHEP Rep. 3, 100284 (2021).
pubmed: 34027340
pmcid: 8122117
Emdin, C. A. et al. Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study. Gastroenterology 160, 1620–1633.e13 (2021).
pubmed: 33310085
Bianco, C. et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J. Hepatol. 74, 775–782 (2021).
pubmed: 33248170
pmcid: 7987554
Thomas, C. E. et al. NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population. Hepatol. Commun. 6, 2310–2321 (2022).
pubmed: 35503778
pmcid: 9426386
Romero-Gómez, M., Zelber-Sagi, S. & Trenell, M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 67, 829–846 (2017).
pubmed: 28545937
Mentella, M. C., Scaldaferri, F., Ricci, C., Gasbarrini, A. & Miggiano, G. A. D. Cancer and mediterranean diet: a review. Nutrients 11, 2059 (2019).
pubmed: 31480794
pmcid: 6770822
Marti-Aguado, D., Clemente-Sanchez, A. & Bataller, R. Cigarette smoking and liver diseases. J. Hepatol. 77, 191–205 (2022).
pubmed: 35131406
Singal, A. K. et al. Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. Hepatology 75, 1026–1037 (2022).
pubmed: 34496071
Janjua, M. et al. Alcohol consumption and cardiovascular outcomes in patients with nonalcoholic fatty liver disease: a population-based cohort study. Hepatol. Commun. 6, 526–534 (2022).
pubmed: 34931492
Lemmer, P. et al. Effects of moderate alcohol consumption in non-alcoholic fatty liver disease. J. Clin. Med. Res. 11, 890 (2022).
Decraecker, M. et al. Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use. Liver Int. 42, 350–362 (2022).
pubmed: 34679242
Tan, E. Z.-Y. et al. Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus. J. Gastroenterol. Hepatol. 36, 751–757 (2021).
pubmed: 32583444
Long, M. T., Massaro, J. M., Hoffmann, U., Benjamin, E. J. & Naimi, T. S. Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 18, 1831–1841.e5 (2020).
pubmed: 31734449
Chang, Y. et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology 69, 64–75 (2019).
pubmed: 30019340
Åberg, F., Helenius-Hietala, J., Puukka, P., Färkkilä, M. & Jula, A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology 67, 2141–2149 (2018).
pubmed: 29164643
Ajmera, V. et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin. Gastroenterol. Hepatol. 16, 1511–1520.e5 (2018).
pubmed: 29378307
pmcid: 6098737
Mitchell, T. et al. Type and pattern of alcohol consumption is associated with liver fibrosis in patients with non-alcoholic fatty liver disease. Am. J. Gastroenterol. 113, 1484–1493 (2018).
pubmed: 29899440
Kimura, T. et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J. Gastroenterol. 24, 1440–1450 (2018).
pubmed: 29632425
pmcid: 5889824
Hagström, H. et al. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 52, 159–165 (2017).
pubmed: 27650916
Kawamura, Y. et al. Effects of alcohol consumption on hepatocarcinogenesis in japanese patients with fatty liver disease. Clin. Gastroenterol. Hepatol. 14, 597–605 (2016).
pubmed: 26707683
Sookoian, S., Flichman, D., Castaño, G. O. & Pirola, C. J. Mendelian randomisation suggests no beneficial effect of moderate alcohol consumption on the severity of nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 44, 1224–1234 (2016).
pubmed: 27778410
Moriya, A. et al. Roles of alcohol consumption in fatty liver: a longitudinal study. J. Hepatol. 62, 921–927 (2015).
pubmed: 25433160
Kwon, H. K., Greenson, J. K. & Conjeevaram, H. S. Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver Int. 34, 129–135 (2014).
pubmed: 23809459
Gunji, T. et al. Modest alcohol consumption has an inverse association with liver fat content. Hepatogastroenterology 59, 2552–2556 (2012).
pubmed: 22534544
Hamaguchi, M. et al. Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. World J. Gastroenterol. 18, 156–167 (2012).
pubmed: 22253522
pmcid: 3257443
Wong, V. W.-S. et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 61, 409–415 (2012).
pubmed: 21846782
Hiramine, Y. et al. Alcohol drinking patterns and the risk of fatty liver in Japanese men. J. Gastroenterol. 46, 519–528 (2011).
pubmed: 20967556
Moriya, A. et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 33, 378–388 (2011).
pubmed: 21118396
Yamada, T. et al. Alcohol drinking may not be a major risk factor for fatty liver in Japanese undergoing a health checkup. Dig. Dis. Sci. 55, 176–182 (2010).
pubmed: 19156520
Cotrim, H. P. et al. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur. J. Gastroenterol. Hepatol. 21, 969–972 (2009).
pubmed: 19194305
Ekstedt, M. et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 44, 366–374 (2009).
pubmed: 19016382
Gunji, T. et al. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. Am. J. Gastroenterol. 104, 2189–2195 (2009).
pubmed: 19550408
Baik, I. & Shin, C. Prospective study of alcohol consumption and metabolic syndrome. Am. J. Clin. Nutr. 87, 1455–1463 (2008).
pubmed: 18469271
Dunn, W., Xu, R. & Schwimmer, J. B. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 47, 1947–1954 (2008).
pubmed: 18454505
Bedogni, G. et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 46, 1387–1391 (2007).
pubmed: 17685472
Dixon, J. B., Bhathal, P. S. & O’Brien, P. E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121, 91–100 (2001).
pubmed: 11438497
Bellentani, S. et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 132, 112–117 (2000).
pubmed: 10644271
Bellentani, S. et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 41, 845–850 (1997).
pubmed: 9462221
pmcid: 1891602
Becker, U. et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 23, 1025–1029 (1996).
pubmed: 8621128
Salameh, H. et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am. J. Gastroenterol. 110, 846–856 (2015).
pubmed: 25964223
Liu, Y.-L. et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 4309 (2014).
pubmed: 24978903
Buch, S. et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat. Genet. 47, 1443–1448 (2015).
pubmed: 26482880
Valenti, L., Alisi, A. & Nobili, V. Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology 55, 661–663 (2012).
pubmed: 22281838
Al-Serri, A. et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J. Hepatol. 56, 448–454 (2012).
pubmed: 21756849
Huang, Y.-S., Wang, L. Y., Chang, C.-H., Perng, C.-L. & Lin, H.-C. Superoxide dismutase 2 genetic variation as a susceptibility risk factor for alcoholic cirrhosis. Alcohol Alcohol. 51, 633–637 (2016).
pubmed: 26873981
Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537–2564 (2021).
pubmed: 33989548
Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann. Hepatol. https://doi.org/10.1016/j.aohep.2023.101133 (2023).
doi: 10.1016/j.aohep.2023.101133
pubmed: 37364816
Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. https://doi.org/10.1016/j.jhep.2023.06.003 (2023).
doi: 10.1016/j.jhep.2023.06.003
pubmed: 37634993
Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology https://doi.org/10.1097/HEP.0000000000000520 (2023).
doi: 10.1097/HEP.0000000000000520
pubmed: 37732990
American Association for the Study of Liver Disease. NAFLD Nomenclature Consensus Meeting High-Level Output. AASLD https://www.aasld.org/news/nafld-nomenclature-consensus-meeting-high-level-output (2022).
Eslam, M., Sanyal, A. J. & George, J. International consensus panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158, 1999–2014.e1 (2020).
pubmed: 32044314
Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 73, 202–209 (2020).
pubmed: 32278004
Kim, D. et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J. Hepatol. 75, 1284–1291 (2021).
pubmed: 34380057
Nguyen, V. H., Le, M. H., Cheung, R. C. & Nguyen, M. H. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin. Gastroenterol. Hepatol. 19, 2172–2181.e6 (2021).
pubmed: 34033923
van Kleef, L. A., de Knegt, R. J. & Brouwer, W. P. Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality. Hepatology 77, 942–948 (2023).
pubmed: 35776631
Méndez-Sánchez, N. et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol. Hepatol. 7, 388–390 (2022).
pubmed: 35248211
Younossi, Z. M. et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 73, 1194–1198 (2021).
pubmed: 32544255
Ratziu, V. et al. The times they are a-changin’ (for NAFLD as well). J. Hepatol. 73, 1307–1309 (2020).
pubmed: 32890593